NEW YORK (GenomeWeb News) – Abbott today reported its molecular diagnostics business rose 1 percent year over year during the second quarter while total sales grew 2 percent.

For the three months ended June 30, molecular diagnostics sales increased to $106 million, compared to $105 million a year ago. In the US, molecular diagnostics rose 7.3 percent year over year to $48 million, while internationally, the business dropped 3.8 percent to $58 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.